New approaches in the treatment of epilepsy
Introduction. Despite the significant progress made in the treatment of epilepsy in recent years, no less than 3040% of patients cannot achieve complete cessation of seizures. Objective. To evaluate new approaches in the epilepsy treatment with nano-sized dosage forms and 3-benzylamino-metilenpir...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2017-09-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/483/376 |
| _version_ | 1828822538617094144 |
|---|---|
| author | Georgiy G. Avakyan Tat'yana A. Voronina Svetlana A. Litvinova Lyubov N. Nerobkova Vadim Yu. Balabanyan Anastasiya A. Nikonova Gagik N. Avakyan |
| author_facet | Georgiy G. Avakyan Tat'yana A. Voronina Svetlana A. Litvinova Lyubov N. Nerobkova Vadim Yu. Balabanyan Anastasiya A. Nikonova Gagik N. Avakyan |
| author_sort | Georgiy G. Avakyan |
| collection | DOAJ |
| description | Introduction. Despite the significant progress made in the treatment of epilepsy in recent years, no less than 3040% of patients cannot achieve complete cessation of seizures.
Objective. To evaluate new approaches in the epilepsy treatment with nano-sized dosage forms and 3-benzylamino-metilenpirrolidin-2,4-dion (beprodone).
Materials and methods. Evaluation of the anticonvulsant activity of nano-phenazepam in comparison with bromine-dihydrochlorophenyl-benzodiazepine (phenazepam) in substances was carried out. 2-aethylium-6-methyl-3-hydroxypyridine succinate (Mexidol) encapsulated on copolymers of lactic and glycolic acids was chosen as the second medicine for evaluation. Beprodone dosed 100 mg/kg intraperitoneally was the third drug assessed in rats. Chronic cobalt-induced epileptogenic focus was chosen as an experimental model. Additional clinical study of beprodone was conducted in 75 patients with epilepsy (men and women, age ranging 1865 years) with uncontrolled focal seizures with or without secondary generalization.
Results. In secondary generalized epilepsy model in rats, nanophenazepam significantly reduced epileptiform discharges in the cortex and hypothalamus along with hippocampus. In the chronic model of cobalt epilepsy, nanomexidol reduced the number of epileptiform discharges 3 times and also stopped the status epilepticus (reducing 7.8 times the number of secondary generalized tonic-clonic seizures). The targets for beprodon are cortical foci and, in the second stage, subcortical foci which generate epileptic activity. In 75 patients with epilepsy who had uncontrolled focal seizures with or without secondary generalization, a significant increase in days without seizures was noted on beprodon; the number of seizures decreased 2 times (p 0.01).
Conclusion. Further investigation of new targets for novel antiepileptic drugs and introduction of the latter into clinical practice can be considered as one of the ways to solve the problem of drug resistance. |
| first_indexed | 2024-12-12T13:15:34Z |
| format | Article |
| id | doaj.art-5380226cc12043c4bb1f95b595ab9616 |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-12-12T13:15:34Z |
| publishDate | 2017-09-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-5380226cc12043c4bb1f95b595ab96162022-12-22T00:23:25ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332017-09-01113152210.18454/ACEN.2017.3.2367New approaches in the treatment of epilepsyGeorgiy G. Avakyan0Tat'yana A. Voronina1Svetlana A. Litvinova2Lyubov N. Nerobkova3Vadim Yu. Balabanyan4Anastasiya A. Nikonova5Gagik N. Avakyan6N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaResearch Institute of Pharmacology named after V.V. ZakusovResearch Institute of Pharmacology named after V.V. ZakusovResearch Institute of Pharmacology named after V.V. ZakusovLomonosov Moscow State UniversityN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaLomonosov Moscow State UniversityIntroduction. Despite the significant progress made in the treatment of epilepsy in recent years, no less than 3040% of patients cannot achieve complete cessation of seizures. Objective. To evaluate new approaches in the epilepsy treatment with nano-sized dosage forms and 3-benzylamino-metilenpirrolidin-2,4-dion (beprodone). Materials and methods. Evaluation of the anticonvulsant activity of nano-phenazepam in comparison with bromine-dihydrochlorophenyl-benzodiazepine (phenazepam) in substances was carried out. 2-aethylium-6-methyl-3-hydroxypyridine succinate (Mexidol) encapsulated on copolymers of lactic and glycolic acids was chosen as the second medicine for evaluation. Beprodone dosed 100 mg/kg intraperitoneally was the third drug assessed in rats. Chronic cobalt-induced epileptogenic focus was chosen as an experimental model. Additional clinical study of beprodone was conducted in 75 patients with epilepsy (men and women, age ranging 1865 years) with uncontrolled focal seizures with or without secondary generalization. Results. In secondary generalized epilepsy model in rats, nanophenazepam significantly reduced epileptiform discharges in the cortex and hypothalamus along with hippocampus. In the chronic model of cobalt epilepsy, nanomexidol reduced the number of epileptiform discharges 3 times and also stopped the status epilepticus (reducing 7.8 times the number of secondary generalized tonic-clonic seizures). The targets for beprodon are cortical foci and, in the second stage, subcortical foci which generate epileptic activity. In 75 patients with epilepsy who had uncontrolled focal seizures with or without secondary generalization, a significant increase in days without seizures was noted on beprodon; the number of seizures decreased 2 times (p 0.01). Conclusion. Further investigation of new targets for novel antiepileptic drugs and introduction of the latter into clinical practice can be considered as one of the ways to solve the problem of drug resistance.https://annaly-nevrologii.com/journal/pathID/article/viewFile/483/376epilepsy, drug resistance, focal seizures, nanophenazepam, nanomexidol, beprodone |
| spellingShingle | Georgiy G. Avakyan Tat'yana A. Voronina Svetlana A. Litvinova Lyubov N. Nerobkova Vadim Yu. Balabanyan Anastasiya A. Nikonova Gagik N. Avakyan New approaches in the treatment of epilepsy Анналы клинической и экспериментальной неврологии epilepsy, drug resistance, focal seizures, nanophenazepam, nanomexidol, beprodone |
| title | New approaches in the treatment of epilepsy |
| title_full | New approaches in the treatment of epilepsy |
| title_fullStr | New approaches in the treatment of epilepsy |
| title_full_unstemmed | New approaches in the treatment of epilepsy |
| title_short | New approaches in the treatment of epilepsy |
| title_sort | new approaches in the treatment of epilepsy |
| topic | epilepsy, drug resistance, focal seizures, nanophenazepam, nanomexidol, beprodone |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/483/376 |
| work_keys_str_mv | AT georgiygavakyan newapproachesinthetreatmentofepilepsy AT tatyanaavoronina newapproachesinthetreatmentofepilepsy AT svetlanaalitvinova newapproachesinthetreatmentofepilepsy AT lyubovnnerobkova newapproachesinthetreatmentofepilepsy AT vadimyubalabanyan newapproachesinthetreatmentofepilepsy AT anastasiyaanikonova newapproachesinthetreatmentofepilepsy AT gagiknavakyan newapproachesinthetreatmentofepilepsy |